BioMarin Pharmaceuticals
BMRN
426 hedge funds and large institutions have $15.6B invested in BioMarin Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 161 increasing their positions, 149 reducing their positions, and 36 closing their positions.
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
28% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 36
2% more funds holding
Funds holding: 418 → 426 (+8)
8% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 149
5% more capital invested
Capital invested by funds: $14.8B → $15.6B (+$725M)
0.46% more ownership
Funds ownership: 97.8% → 98.26% (+0.46%)
13% less call options, than puts
Call options by funds: $84.4M | Put options by funds: $97.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$305M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$100M |
| 3 |
Millennium Management
New York
|
+$80.2M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$79.7M |
| 5 |
UIM
USS Investment Management
London,
United Kingdom
|
+$67.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$75.5M |
| 2 |
SIG
Senator Investment Group
New York
|
-$70.2M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$67.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$61.1M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$56.1M |
BMRN Hedge Fund Activity: Q2 2017 in Review
426 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2017, worth a combined $15.6B — up 4.9% from $14.8B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new BMRN positions and 36 closed out — a net gain of 10 holders — while 161 added to existing stakes and 149 trimmed.
The largest buyer was Jennison Associates, adding an estimated $305M. The largest seller was PFM Health Sciences, cutting an estimated $75.5M.
- 426 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2017, up from 418 in Q1 2017.
- Funds reported $15.6B of BioMarin Pharmaceuticals stock for Q2 2017, up 4.9% quarter-over-quarter.
- 46 funds opened new BioMarin Pharmaceuticals positions in Q2 2017 and 36 closed out, a net change of +10 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2017 was Jennison Associates, an estimated $305M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2017 was PFM Health Sciences, an estimated $75.5M sold.
Based on aggregated 13F filings for Q2 2017.